suramin has been researched along with Fibrous Dysplasia of Bone in 1 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Fibrous Dysplasia of Bone: A disease of bone marked by thinning of the cortex by fibrous tissue containing bony spicules, producing pain, disability, and gradually increasing deformity. Only one bone may be involved (FIBROUS DYSPLASIA, MONOSTOTIC) or several (FIBROUS DYSPLASIA, POLYOSTOTIC).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lv, M | 1 |
| Li, X | 1 |
| Huang, Y | 1 |
| Wang, N | 1 |
| Zhu, X | 1 |
| Sun, J | 1 |
1 other study available for suramin and Fibrous Dysplasia of Bone
| Article | Year |
|---|---|
Inhibition of fibrous dysplasia via blocking GsĪ± with suramin sodium loaded with an alendronate-conjugated polymeric drug delivery system.
Topics: Alendronate; Animals; Bone Marrow Cells; Cell Culture Techniques; Cell Line; Drug Carriers; Durapati | 2016 |